Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 19, 2014, Pages 4708-4713

  Wen, Wandong ^a,b   Young, Summer E ^b   Duvernay, Matthew T ^b   Schulte, Michael L ^c   Nance, Kellie D ^c   Melancon, Bruce J ^b,d   Engers, Julie ^b,d   Locuson, Charles W ^b,d   Wood, Michael R ^b,c,d   Daniels, J Scott ^b,d   Wu, Wenjun ^a   Lindsley, Craig W ^b,c,d   Hamm, Heidi E ^b   Stauffer, Shaun R ^b,c,d  

^a NORTHWEST A F UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ML354; PAR 4 antagonist; Protease activated receptor 4

Indexed keywords

4 (1 BENZYL 1H INDAZOL 3 YL)BENZOIC ACID ETHYL ESTER; INDOLE DERIVATIVE; ML 354; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VU 0478944; VU 0478946; VU 0478971; VU 0478972; VU 0478973; VU 0478975; VU 0518413; APOPTOSIS REGULATORY PROTEIN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; VU0099704;

ALKYLATION; ARTICLE; BROMINATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG PURIFICATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTROPHILICITY; HUMAN; HYDROGEN BOND; IC50; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; PHARMACOPHORE; PLASMA PROTEIN BINDING; REDUCTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DEVELOPMENT; METABOLISM; SYNTHESIS;

APOPTOSIS REGULATORY PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; INDOLES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907189440     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.08.021     Document Type: Article

References (18)

1. Z.M. Ruggeri Platelets Atherothrombosis Nat. Med. 8 2002 1227
2. M.N. Adams, R. Ramachandran, M.-K. Yau, J.Y. Suen, D.P. Fairlie, M.D. Hollenberg, and J.D. Hooper Pharm. Ther. 130 2011 248
3. S. Coughlin Nature 407 2000 258
4. M.L. Kahn, Y.W. Zheng, W. Huang, V. Bigornia, D. Zeng, S. Moff, R.V. Farese Jr., C. Tam, and S.R. Coughlin Nature 394 1998 690
5. Y. Mao, M. Zhang, R. Tuma, and S. Kunapuli J. Cereb. Blood Flow Metab. 30 2010 1044
6. E.R. Vandendries, J.R. Hamilton, S.R. Coughlin, B. Furie, and B.C. Furie Proc. Natl. Acad. Sci. U.S.A. 104 2007 288
7. I. Cornelissen, D. Palmer, T. David, L. Wilsbacher, C. Concengco, P. Conley, A. Pandey, and S.R. Coughlin Proc. Natl. Acad. Sci. U.S.A. 107 2010 18605
8. G. Sambrano, E. Weiss, Y. Zheng, W. Huang, and S. Coughlin Nature 413 2001 74
9. P. Henrih-Noack, M. Riek-Burchardt, K. Baldauf, G. Reiser, and K. Reymann Brain Res. 1070 2006 232
10. See http://www.mercknewsroom.com and http://www.fda.gov for May 2014 Zontivity™ press releases.
11. For information on the MLPCN and information on how to request probe compounds, such as ML354, see: http://mli.nih.gov/mli/mlpcn/.
12. F.-Y. Lee, J.-C. Lien, L.-J. Huang, T.-M. Huang, S.-C. Tsai, C.-M. Teng, C.-C. Wu, F.-C. Cheng, and S.-C. Kuo J. Med. Chem. 44 2001 3746
13. H.-S. Chen, S.-C. Kuo, C.-M. Teng, F.-Y. Lee, J.-P. Want, Y.-C. Lee, C.-W. Kuo, C.-C. Huang, C.-C. Wu, and L.-J. Huang Bioorg. Med. Chem. 16 2008 1262
14. S.E. Young, M.T. Duvernay, M.L. Schulte, C.W. Lindsley, and H.E. Hamm PLoS ONE 8 2013 e65528
15. G.F. Smith Prog. Med. Chem. 50 2011 1
16. J. Kou-San Microbiol. Mol. Biol. Rev. 74 2012 250
17. Q. Cai, Z. Li, J. Wei, C. Ha, C. Pei, and K. Ding Chem. Commun. 2009 7581
18. N.A. Meanwell J. Med. Chem. 54 2011 2529